MTOR and clear cell renal carcinoma: In clear cell renal cell carcinoma studies, the mTOR inhibitor Everolimus has been shown to significantly enhance ferroptosis induced by Erastin and RSL3, through a synergistic mechanism that promotes lipid peroxidation and ROS accumulation, which holds promise for overcoming resistance to mTOR monotherapy (133).